Bevacizumab
From Proteopedia
(Difference between revisions)
| (4 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | < | + | <StructureSection load='' size='350' side='right' scene='Bevacizumab/Ba/1' caption='Model Bevacizumab, also known as Avastin (PDB code [[1igt]])'> |
| + | __TOC__ | ||
| + | |||
===Better Known as: Avastin=== | ===Better Known as: Avastin=== | ||
* Marketed By: Genentech & Roche<br /> | * Marketed By: Genentech & Roche<br /> | ||
| Line 44: | Line 46: | ||
! 10 | ! 10 | ||
|} | |} | ||
| - | + | </StructureSection> | |
===References=== | ===References=== | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||
__NOTOC__ | __NOTOC__ | ||
Current revision
| |||||||||||
References
- ↑ Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106(4):148-56. PMID:11815711
- ↑ Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant. 2007 Mar;22(3):975. Epub 2006 Nov 8. PMID:17093010 doi:10.1093/ndt/gfl664
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Joel L. Sussman, Alexander Berchansky
